328 related articles for article (PubMed ID: 37072660)
1. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.
Bodó I; Amine I; Boban A; Bumbea H; Kulagin A; Lukina E; Piekarska A; Zupan IP; Sokol J; Windyga J; Cermak J
Adv Ther; 2023 Jun; 40(6):2752-2772. PubMed ID: 37072660
[TBL] [Abstract][Full Text] [Related]
2. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
Front Immunol; 2019; 10():1157. PubMed ID: 31258525
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.
Wong R; Fishman J; Wilson K; Yeh M; Al-Adhami M; Zion A; Yee CW; Huynh L; Duh MS
Adv Ther; 2023 Apr; 40(4):1571-1589. PubMed ID: 36750531
[TBL] [Abstract][Full Text] [Related]
4. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
Heo YA
Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
[TBL] [Abstract][Full Text] [Related]
5. Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
Hillmen P; Szer J; Weitz I; Röth A; Höchsmann B; Panse J; Usuki K; Griffin M; Kiladjian JJ; de Castro C; Nishimori H; Tan L; Hamdani M; Deschatelets P; Francois C; Grossi F; Ajayi T; Risitano A; Peffault de Latour R
N Engl J Med; 2021 Mar; 384(11):1028-1037. PubMed ID: 33730455
[TBL] [Abstract][Full Text] [Related]
6. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
[TBL] [Abstract][Full Text] [Related]
7. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
[TBL] [Abstract][Full Text] [Related]
8. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Lee JW; Kulasekararaj AG
Expert Opin Biol Ther; 2020 Mar; 20(3):227-237. PubMed ID: 32011183
[No Abstract] [Full Text] [Related]
9. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Ariceta G
Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
[TBL] [Abstract][Full Text] [Related]
10. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
[TBL] [Abstract][Full Text] [Related]
11. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
Versino F; Fattizzo B
Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
[TBL] [Abstract][Full Text] [Related]
12. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
Frieri C; Peffault de Latour R; Sicre De Fontbrune F
Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
[TBL] [Abstract][Full Text] [Related]
14. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
Risitano AM
Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
[TBL] [Abstract][Full Text] [Related]
15. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
[No Abstract] [Full Text] [Related]
16. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
Risitano AM; Peffault de Latour R; Marano L; Frieri C
Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
[TBL] [Abstract][Full Text] [Related]
17. Safety of current treatments for paroxysmal nocturnal hemoglobinuria.
Lee SE; Lee JW
Expert Opin Drug Saf; 2021 Feb; 20(2):171-179. PubMed ID: 33249943
[No Abstract] [Full Text] [Related]
18. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
Gavriilaki E; de Latour RP; Risitano AM
Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
[TBL] [Abstract][Full Text] [Related]
19. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
20. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]